Table 6.
Baseline characteristics in multiple myeloma cohort.
| Early G-CSF* (N = 24) | Controla (N = 23) | Total (N = 47) | |
|---|---|---|---|
| Age at CAR T | |||
| Median [Min, Max] | 63 [46, 77] | 64 [41, 76] | 63 [41, 77] |
| Sex | |||
| Female | 7 (29.2%) | 9 (39.1%) | 16 (34.0%) |
| Disease type | |||
| IgG | 14 (58.3%) | 9 (39.1%) | 23 (48.9%) |
| IgA | 5 (20.8%) | 6 (26.1%) | 11 (23.4%) |
| Light chain | 5 (20.8%) | 7 (30.4%) | 12 (25.5%) |
| Other | 0 (0%) | 1 (4.3%) | 1 (2.1%) |
| Number of prior lines of therapy | |||
| 1–3 | 6 (25.0%) | 5 (21.7%) | 11 (23.4%) |
| 4–6 | 10 (41.7%) | 13 (56.5%) | 23 (48.9%) |
| ≥7 | 8 (33.3%) | 5 (21.7%) | 13 (27.7%) |
| Prior autologous hematopoietic cell transplant | |||
| Yes | 13 (54.2%) | 14 (60.9%) | 27 (57.4%) |
| ECOG performance status at CAR T | |||
| 0 | 13 (54.2%) | 14 (60.9%) | 27 (57.4%) |
| 1 | 9 (37.5%) | 9 (39.1%) | 18 (38.3%) |
| ≥2 | 2 (8.3%) | 0 (0%) | 2 (4.3%) |
| Time from diagnosis to CAR T (months) | |||
| Median [Min, Max] | 70 [7, 149] | 68 [8, 130] | 70 [7, 149] |
| White blood cell count (×109/L)b | |||
| Median [Min, Max] | 3.24 [1.82, 7.31] | 3.63 [1.32, 12.1] | 3.40 [1.32, 12.1] |
| Absolute neutrophil count (×109/L)b | |||
| Median [Min, Max] | 2.09 [0.92, 4.82] | 2.23 [0.90, 9.82] | 2.18 [0.90, 9.82] |
| Hemoglobin (g/dL)b | |||
| Median [Min, Max] | 9.6 [6.9, 13.3] | 9.9 [5.7, 12.8] | 9.7 [5.7, 13.3] |
| Platelet Count (×109/L)b | |||
| Median [Min, Max] | 91 [25, 271] | 169 [52, 381] | 122 [25, 381] |
*Early G-CSF group received G-CSF within ≤2 days after CAR T.
aControl group either received G-CSF ≥ 3 days after CAR T (N = 21) or were not exposed to G-CSF (N = 2).
bMost recent values measured immediately prior to initiation of lymphodepletion chemotherapy.